Inclusion Criteria:

          1. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.

          2. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale

          3. Adequate organ function

          4. In subjects requiring biliary decompression, metal stent or drainage using
             percutaneous transhepatic cholangiogram (PTC) are allowed

        Exclusion Criteria:

          1. Immunodeficiency or taking steroid or any other form of immunosuppressive therapy

          2. Has a plastic biliary stent for decompression

          3. Metastatic disease

          4. Prior treatment for pancreatic cancer (other than 4-8 cycles of Folfirinox) or prior
             treatment with radiation for other diagnoses to the expected pancreatic cancer
             treatment area

          5. Active autoimmune disease

          6. Pregnancy or Nursing

          7. Known history of Human Immunodeficiency Virus (HIV) or Hepatitis B or C

          8. Prior monoclonal antibody within 4 weeks prior to study Day 1

          9. Known additional malignancy that is progressing or requires active treatment

         10. Evidence of interstitial lung disease or active, non-infectious pneumonitis

         11. Active infection requiring systemic therapy

         12. Prior therapy with an anti-Program Death (PD-1) antibody, anti-PD-L1, anti-PD-L2, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody